Q-omics provides the consensus-scored LRRC4B profile across patient tissues and cancer cell-line models. LRRC4B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LRRC4B is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, LRRC4B RNA expression shows 16,776 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KICH, and GBM as cancer lineages where LRRC4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC4B survival associations across molecular data types. LRRC4B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC4B RNA expression–survival associations across cancer types. High LRRC4B expression shows unfavorable associations in KIRP and OV, but favorable associations in UCEC, HNSC, PAAD and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LRRC4B RNA expression.
This table summarizes LRRC4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC4B shows lower tumor expression in KICH, LUAD, LUSC, BLCA, UCEC and BRCA. The KICH box plot shows higher LRRC4B RNA expression in normal versus tumor tissue (log2 FC = −0.841, t-test p < 0.001).
This table shows molecular features associated with LRRC4B in patient tissues and cancer cell lines. In patient samples, LRRC4B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
